Total Payments
$729,795
2024 Payments
$77,043
Companies
28
Transactions
470
Medicare Patients
815
Medicare Billing
$227,698
Payment Breakdown by Category
Other$337,981 (46.3%)
Consulting$291,912 (40.0%)
Travel$73,830 (10.1%)
Research$18,074 (2.5%)
Food & Beverage$7,899 (1.1%)
Education$98.65 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $337,981 | 104 | 46.3% |
| Consulting Fee | $291,912 | 93 | 40.0% |
| Travel and Lodging | $73,830 | 160 | 10.1% |
| Unspecified | $18,074 | 14 | 2.5% |
| Food and Beverage | $7,899 | 98 | 1.1% |
| Education | $98.65 | 1 | 0.0% |
Payments by Type
General
$711,721
456 transactions
Research
$18,074
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Foundation Medicine, Inc. | $224,104 | 61 | $0 (2023) |
| TAIHO ONCOLOGY, INC. | $120,214 | 84 | $0 (2024) |
| Celgene Corporation | $114,360 | 75 | $0 (2021) |
| Ipsen Biopharmaceuticals, Inc | $96,725 | 83 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $60,689 | 59 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $41,021 | 25 | $0 (2024) |
| F. Hoffmann-La Roche AG | $12,842 | 10 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $9,075 | 5 | $0 (2024) |
| Genentech, Inc. | $8,105 | 12 | $0 (2024) |
| Astellas Pharma US Inc | $7,755 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $77,043 | 51 | TAIHO ONCOLOGY, INC. ($29,470) |
| 2023 | $89,167 | 42 | Foundation Medicine, Inc. ($43,877) |
| 2022 | $98,254 | 35 | Foundation Medicine, Inc. ($68,927) |
| 2021 | $86,499 | 46 | Foundation Medicine, Inc. ($40,000) |
| 2020 | $26,297 | 32 | Ipsen Biopharmaceuticals, Inc ($9,515) |
| 2019 | $136,218 | 99 | Ipsen Biopharmaceuticals, Inc ($40,083) |
| 2018 | $133,361 | 112 | Celgene Corporation ($57,962) |
| 2017 | $82,956 | 53 | Celgene Corporation ($44,886) |
All Payment Transactions
470 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $133.27 | General |
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $860.00 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $32.11 | General |
| Category: Oncology | ||||||
| 10/28/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $8,910.00 | General |
| Category: Oncology | ||||||
| 10/28/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug) | Travel and Lodging | In-kind items and services | $261.20 | General |
| Category: Oncology | ||||||
| 10/28/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug) | Travel and Lodging | In-kind items and services | $169.46 | General |
| Category: Oncology | ||||||
| 10/28/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug) | Travel and Lodging | In-kind items and services | $133.98 | General |
| Category: Oncology | ||||||
| 10/28/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug) | Food and Beverage | In-kind items and services | $100.74 | General |
| Category: Oncology | ||||||
| 10/28/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug) | Travel and Lodging | In-kind items and services | $70.00 | General |
| Category: Oncology | ||||||
| 10/28/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug) | Travel and Lodging | In-kind items and services | $70.00 | General |
| Category: Oncology | ||||||
| 10/28/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug) | Food and Beverage | Cash or cash equivalent | $13.78 | General |
| Category: Oncology | ||||||
| 10/28/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug) | Food and Beverage | Cash or cash equivalent | $5.23 | General |
| Category: Oncology | ||||||
| 10/23/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| Category: Oncology | ||||||
| 10/16/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,560.00 | General |
| Category: Oncology | ||||||
| 10/16/2024 | Legend Biotech USA Inc. | — | Consulting Fee | Cash or cash equivalent | $2,555.00 | General |
| 10/16/2024 | SEAGEN INC. | — | Education | In-kind items and services | $98.65 | General |
| 10/10/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Travel and Lodging | In-kind items and services | $650.57 | General |
| Category: Oncology | ||||||
| 10/10/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 10/08/2024 | Astellas Pharma US Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,160.00 | General |
| 10/08/2024 | Astellas Pharma US Inc | — | Travel and Lodging | Cash or cash equivalent | $752.59 | General |
| 10/08/2024 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $108.38 | General |
| 10/02/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,610.00 | General |
| Category: Oncology | ||||||
| 10/02/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,500.00 | General |
| Category: Oncology | ||||||
| 10/02/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug) | Travel and Lodging | In-kind items and services | $817.49 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA FOLLOWING DEFINITIVE CONCURRENT CHEMORADIOTHERAPY | Genentech, Inc. | $5,368 | 5 |
| A phase 1, open-label, multicenter, safety study of nivolumab (bms-936558) in combination with nab-pacitaxel plus or minus gemcitabine in pancreatic cancer, nab-paclitaxel/carboplatin in stage iiib/iv non-small cell lung cancer or nab-paclitaxel in metastastic breast cancer (ABI-007-ST-001) | Celgene Corporation | $4,896 | 1 |
| Unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy | Genentech, Inc. | $2,429 | 3 |
| AX-CL-NSCLC-Alliance-006861 | Celgene Corporation | $1,905 | 1 |
| BI754111 & BI754091 BI75411 combination | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,873 | 1 |
| A PHASE IbII, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA MORPHEUS-PANCREATIC CANCER | F. Hoffmann-La Roche AG | $1,161 | 2 |
| ABI-007-ST-001 - A phase 1, open-label, multicenter, safety study of nivolumab (bms-936558) in combination with nab-pacitaxel plus or minus gemcitabine in pancreatic cancer, nab-paclitaxel/carboplatin in stage iiib/iv | Celgene Corporation | $442.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 152 | 386 | $183,172 | $34,192 |
| 2022 | 6 | 177 | 463 | $207,189 | $44,666 |
| 2021 | 7 | 257 | 809 | $361,958 | $87,020 |
| 2020 | 6 | 229 | 598 | $276,266 | $61,820 |
Total Patients
815
Total Services
2,256
Medicare Billing
$227,698
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 50 | 204 | $112,812 | $20,815 | 18.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 52 | 97 | $34,435 | $6,996 | 20.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 22 | 22 | $16,324 | $2,841 | 17.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 14 | 47 | $15,745 | $2,797 | 17.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 14 | 16 | $3,856 | $743.40 | 19.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 39 | 164 | $88,068 | $18,104 | 20.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 70 | 171 | $58,995 | $12,258 | 20.8% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2022 | 15 | 48 | $22,560 | $7,664 | 34.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 21 | 21 | $15,120 | $2,752 | 18.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 14 | 36 | $17,064 | $2,732 | 16.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 18 | 23 | $5,382 | $1,157 | 21.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 59 | 277 | $144,317 | $30,482 | 21.1% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2021 | 34 | 185 | $84,360 | $29,725 | 35.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 88 | 213 | $71,355 | $15,979 | 22.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 21 | 70 | $32,200 | $5,528 | 17.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 17 | 17 | $11,883 | $2,406 | 20.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 22 | 30 | $6,810 | $1,517 | 22.3% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 16 | 17 | $11,033 | $1,384 | 12.5% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2020 | 32 | 167 | $73,981 | $26,598 | 36.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 75 | 235 | $118,910 | $19,690 | 16.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 66 | 114 | $37,509 | $6,717 | 17.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 18 | 44 | $19,668 | $3,615 | 18.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 26 | 26 | $17,654 | $3,294 | 18.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 12 | 12 | $8,544 | $1,906 | 22.3% |
About Dr. Ben George, M.D
Dr. Ben George, M.D is a Internal Medicine healthcare provider based in Rochester, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/18/2007. The National Provider Identifier (NPI) number assigned to this provider is 1295930519.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ben George, M.D has received a total of $729,795 in payments from pharmaceutical and medical device companies, with $77,043 received in 2024. These payments were reported across 470 transactions from 28 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($337,981).
As a Medicare-enrolled provider, George has provided services to 815 Medicare beneficiaries, totaling 2,256 services with total Medicare billing of $227,698. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology, Medical Oncology
- Location Rochester, MN
- Active Since 06/18/2007
- Last Updated 08/26/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1295930519
Products in Payments
- FOUNDATIONONE CDX (Device) $146,367
- Abraxane (Drug) $68,006
- LONSURF (Drug) $67,630
- ONIVYDE (Drug) $59,734
- FOUNDATIONONE LIQUID (Device) $55,300
- Lonsurf (Drug) $48,154
- IMFINZI (Biological) $40,789
- Onivyde (Drug) $28,513
- FOUNDATIONACT (Device) $16,000
- FRUZAQLA (Drug) $9,075
- Lenvima (Drug) $6,507
- TECENTRIQ (Biological) $5,668
- Somatuline Depot (Drug) $4,935
- Cabometyx (Drug) $4,780
- SOMATULINE DEPOT (Drug) $4,453
- Tecentriq (Biological) $3,590
- Somatuline Depot 120mg-.5ml (Drug) $3,211
- TheraSphere (Device) $2,813
- OPDIVO (Biological) $2,300
- Avastin (Biological) $1,758
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Rochester
John Kisiel, M.d, M.D
Internal Medicine — Payments: $550,377
Internal Medicine $550,377
Gregory Poland, M.d, M.D
Internal Medicine — Payments: $532,099
Internal Medicine $532,099
Christopher Ritchlin, Md, MD
Internal Medicine — Payments: $512,889
Internal Medicine $512,889
Scott Feitell, D.o, D.O
Internal Medicine — Payments: $471,187
Internal Medicine $471,187
Prashant Kapoor, Md, MD
Internal Medicine — Payments: $403,295
Internal Medicine $403,295
Irina Bancos, M.d, M.D
Internal Medicine — Payments: $360,053
Internal Medicine $360,053